Chronic Lymphocytic Leukemia
October 2020 Issue

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content, Inc.

1:Highlights from ASCO 2020: updates on the treatment of chronic lymphocytic leukemia.
Authors:Dolan S, Christofides A, Doucette S, Shafey M
Institution:Dalhousie University, St. John, NB. University of Calgary, Calgary, AB.
Journal:Curr Oncol. 2020 Aug;27(4):e420-e432. doi: 10.3747/co.27.7009. Epub 2020 Aug 1.

2:Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Authors:Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Tausch E, Schary W, Ritgen M, Wendtner CM, Kreuzer KA, Eichhorst B, Stilgenbauer S, Hallek M, Fischer K
Institution:Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany.
Journal:Lancet Oncol. 2020 Sep;21(9):1188-1200. doi: 10.1016/S1470-2045(20)30443-5.

3:When CLL meets COVID-19.
Authors:Montserrat E
Institution:University of Barcelona.
Journal:Blood. 2020 Sep 3;136(10):1115-1116. doi: 10.1182/blood.2020008092.

4:LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia.
Authors:Liu W, Burger JA, Xu J, Tang Z, Toruner G, Khanlari M, Medeiros LJ, Tang G
Institution:Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030-4009, USA.
Journal:Ann Hematol. 2020 Oct;99(10):2343-2349. doi: 10.1007/s00277-020-04223-y. Epub 2020 Aug 24.

5:Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
Authors:Kreuzberger N, Damen JA, Trivella M, Estcourt LJ, Aldin A, Umlauff L, Vazquez-Montes MD, Wolff R, Moons KG, Monsef I, Foroutan F, Kreuzer KA, Skoetz N
Institution:Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Colo Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne,
Journal:Cochrane Database Syst Rev. 2020 Jul 31;7:CD012022. doi: 10.1002/14651858.CD012022.pub2.

6:Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy.
Authors:Helleberg M, Niemann CU, Moestrup KS, Kirk O, Lebech AM, Lane C, Lundgren J
Institution:Department of Infectious Diseases, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Journal:J Infect Dis. 2020 Sep 1;222(7):1103-1107. doi: 10.1093/infdis/jiaa446.

7:Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Authors:Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA
Institution:Memorial Sloan-Kettering Cancer Center, New York, NY. Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Journal:Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.

8:COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Authors:Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P
Institution:Universita Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy.
Journal:Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.

9:Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Authors:Pula B, Iskierka-Jazdzewska E, Dlugosz-Danecka M, Szymczyk A, Hus M, Szeremet A, Drozd-Sokolowska J, Waszczuk-Gajda A, Zaucha JM, Holojda J, Piszczek W, Steckiewicz P, Wojciechowska M, Osowiecki M, Knopinska-Posluszny W, Dudzinski M, Zawirska D, Subocz E, Halka J, Pluta A, Wichary R, Kumiega B, Budziszewska BK, Jurczak W, Lech-Maranda E, Giannopoulos K, Robak T, Jamroziak K
Institution:Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland Department of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Journal:Anticancer Res. 2020 Jul;40(7):4059-4066. doi: 10.21873/anticanres.14403.

10:Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Authors:Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC
Institution:Willamette Valley Cancer Institute/US Oncology, Eugene, OR, USA. The Ohio State University Comprehensive Cancer Center and Division of Hematology, Columbus, OH, USA. Electronic address:
Journal:Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2.

11:Duvelisib for the treatment of chronic lymphocytic leukemia.
Authors:Frustaci AM, Tedeschi A, Deodato M, Zamprogna G, Cairoli R, Montillo M
Institution:Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Piazza Ospedale Maggiore 3 , Milano, Italy.
Journal:Expert Opin Pharmacother. 2020 Aug;21(11):1299-1309. doi: 10.1080/14656566.2020.1751123. Epub 2020 Apr 15.

12:Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Authors:Kienle DL, Stilgenbauer S
Institution:Department of Internal Medicine III, Ulm University , Ulm, Germany.
Journal:Expert Opin Pharmacother. 2020 Jun;21(8):917-929. doi: 10.1080/14656566.2020.1737010. Epub 2020 Mar 12.

13:Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Authors:Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghea M, Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meûter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P
Institution:Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Division of Experimental Oncology, IRCCS Ospedale San Raffaele, Milan, Italy.
Journal:Am J Hematol. 2020 Jun;95(6):604-611. doi: 10.1002/ajh.25766. Epub 2020 Mar 14.

14:Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group.
Authors:Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U, Jacobs G, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S, Hallek M
Institution:Department of Internal Medicine I, Munchen Klinik Schwabing, Munich, Germany. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
Journal:Leukemia. 2020 Apr;34(4):1038-1051. doi: 10.1038/s41375-020-0727-y. Epub 2020 Feb 10.

15:Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on.
Authors:Molica S, Matutes E, Tam C, Polliack A
Institution:Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy. Department of Hematology, Hadassah-Hebrew-University Medical Center, Jerusalem, Israel.
Journal:Hematol Oncol. 2020 Apr;38(2):129-136. doi: 10.1002/hon.2695. Epub 2019 Dec 10.

16:Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia.
Authors:Robbertz AS, Weiss DM, Awan FT, Byrd JC, Rogers KA, Woyach JA
Institution:Department of Psychology, The Ohio State University, 1835 Neil Avenue, Columbus, OH, 43210, USA.
Journal:Support Care Cancer. 2020 Apr;28(4):1799-1807. doi: 10.1007/s00520-019-04991-y. Epub 2019 Jul 22.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount

Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 6, 2021
170 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
  • Timely, up to date content with free guidebook updates for 1 year.
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
  • Over 130,000 Guidebooks Sold
  • 100% Risk Free Money Back Guarantee


The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:


Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook


Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook

Order by Phone

Call Toll Free in the U.S.

From Outside the U.S.

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders


Coupon Expires: April 6, 2021

What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
Coedpoeth, United Kingdom

Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2021 Medifocus, Inc. All rights reserved.